10-Q: Revvity Reports Q2 Revenue Growth Amid Margin Pressures

Revvity, Inc. reported a 4% increase in Q2 2025 revenue, reaching $720.3 million, driven by growth in both Life Sciences and Diagnostics segments, despite a decline in gross margins.

Summary

• Total revenue for the second quarter of fiscal year 2025 increased by 4% to $720.3 million, up from $691.7 million in Q2 2024.
• Life Sciences segment revenue grew by 5% to $365.9 million, primarily due to a $17.1 million increase in Software revenue.
• Diagnostics segment revenue increased by 3% to $354.4 million, driven by growth in Immunodiagnostics and Reproductive Health businesses.
• Consolidated gross margins decreased by 123 basis points to 54.5% in Q2 2025, down from 55.7% in Q2 2024, mainly due to increased tariffs and product mix shift.
• Operating income from continuing operations rose to $90.76 million in Q2 2025 from $85.724 million in Q2 2024, with operating margins increasing by 20 basis points.
• Net income for Q2 2025 was $53.948 million, a decrease from $55.360 million in Q2 2024.
• Basic earnings per share for Q2 2025 was $0.46, compared to $0.45 in Q2 2024, benefiting from a significantly lower loss from discontinued operations.
• Net cash provided by operating activities for the six months ended June 29, 2025, decreased to $262.473 million from $306.184 million in the prior year period.
• The company repurchased $447.5 million of common stock during the six months ended June 29, 2025, with $414.5 million remaining available under the repurchase program as of that date.
• Cash and cash equivalents stood at $991.849 million as of June 29, 2025, a decrease from $1,163.396 million at December 29, 2024.
• Long-term debt increased to $3,214.324 million as of June 29, 2025, from $3,150.476 million at December 29, 2024.

Sentiment

Score: 6

Explanation: The company shows solid revenue growth and an increase in operating income, indicating demand for its products and some operational efficiency gains. The significant share repurchase program is a strong positive for shareholder value. However, these positives are tempered by a notable decline in gross margins due to tariffs and product mix, a decrease in net income for the quarter, and a significant reduction in operating cash flow. The mixed financial performance, coupled with ongoing cost pressures, suggests a neutral to slightly positive outlook.

Positives

• Overall revenue increased by 4% for the second quarter and 3% for the six-month period, demonstrating continued top-line growth.
• Operating income from continuing operations increased by $5.036 million for the quarter and $33.15 million for the six-month period, indicating improved operational efficiency.
• Consolidated operating margins improved by 20 basis points in the second quarter due to sales volume leverage and productivity gains.
• The Life Sciences segment saw a 5% revenue increase, driven by strong performance in Software revenue, reflecting successful digital capabilities investments.
• The Diagnostics segment achieved a 3% revenue increase, with growth in both Immunodiagnostics and Reproductive Health businesses.
• Loss from discontinued operations significantly decreased to $1.274 million in Q2 2025 from $17.246 million in Q2 2024, positively impacting net income.
• The company executed substantial share repurchases totaling $447.5 million in the first six months of fiscal year 2025, signaling confidence and returning capital to shareholders.
• Interest expense decreased due to a lower debt balance following the repayment of senior unsecured notes that matured in September 2024.

Negatives

• Consolidated gross margins decreased by 123 basis points in the second quarter, primarily due to increased tariffs and an unfavorable product mix shift.
• Net income for the second quarter decreased to $53.948 million from $55.360 million in the prior year period.
• Net cash provided by operating activities for the six-month period decreased by $64.1 million, primarily due to timing of collections and payments, increased variable incentive compensation, and tax payments.
• Cash and cash equivalents decreased by $171.547 million from December 2024 to June 2025.
• Life Sciences Solutions revenue experienced a slight decrease of $4.9 million for the six-month period.
• Research and development expenses increased by 11% for the quarter and 9% for the six-month period, driven by unfavorable foreign exchange rates and new product development investments.
• Significant litigation matters and settlements expenses increased to $11.7 million for the six-month period ended June 29, 2025, compared to $6.3 million in the prior year period.
• Restructuring and other costs, net, increased to $11.2 million for the three months ended June 29, 2025, from $9.8 million in the prior year period.
• The company estimates tariffs could increase cost of revenue by approximately $25 million for the current fiscal year, resulting in an estimated $20 million decrease to gross margin.

Risks

• Decline in markets or anticipated growth due to general economic conditions, uncertainties in government/industrial funding, or unfavorable changes in government regulations.
• Adverse effects from global economic and political conditions, including inflation, recession, trade barriers, tariffs, wars, conflicts, or operational disruptions at facilities.
• Failure to introduce new products in a timely manner, leading to loss of market share or inability to achieve revenue growth targets.
• Inability to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses, or make them profitable.
• Aggressive competition from numerous competitors, potentially requiring price adjustments or leading to loss of market share.
• Significant fluctuation in quarterly operating results due to factors like demand, competitive pressures, economic activity, trade policy, tax laws, raw material costs, and foreign exchange rates.
• Significant disruption in third-party package delivery and import/export services, or significant price increases for these services.
• Disruptions in the supply of raw materials, key components, and other goods from limited or single-source suppliers.
• Inability to retain key personnel, including executive officers, management, and technical staff, or failure to execute leadership succession plans.
• Significant disruption in, or breach of security of, information technology systems (including cybercrime), or failure to implement new systems successfully.
• Failure to realize the full value of intangible assets, potentially leading to impairment charges.
• Inadequate protection of intellectual property (patents, trade secrets, trademarks) or challenges to their validity.
• Inability to renew licenses or loss of licensed rights, potentially requiring cessation of product sales or loss of competitive advantage.
• Exposure to product and other liability claims for which the company could have substantial liability.
• Failure to maintain satisfactory compliance with regulations of the United States Food and Drug Administration and other governmental agencies.
• Non-compliance with stringent data privacy and information security laws and regulations.
• Changes in governmental regulations that may reduce demand for products or increase expenses.
• Failure to comply with extensive laws and regulations in the highly regulated healthcare industry.
• Economic, political, and other risks associated with foreign operations, including currency exchange rate fluctuations, trade protection measures, and differing tax laws.
• Substantial outstanding debt impacting ability to obtain future financing and limiting other expenditures.
• Restrictive covenants in senior unsecured revolving credit facility and other debt instruments limiting company activities.
• Fluctuations in the company's share price due to various market and operational factors.
• Potential reduction or elimination of common stock dividends in the future to fund investments or conserve capital.

Future Outlook

The effective tax rate on continuing operations, before discrete items, is expected to be approximately 20% during fiscal year 2025. The company does not currently believe the enactment of the One Big Beautiful Bill Act (OBBBA) will materially impact 2025 earnings, with further evaluation for subsequent years. Tariffs are estimated to increase cost of revenue by approximately $25 million for the current fiscal year, but mitigating actions are anticipated to limit the gross margin decrease to approximately $20 million. Management expects to continue using proceeds from the sale of the Applied, Food and Enterprise Services businesses for debt retirement, opportunistic share repurchases, and strategic acquisitions. The Board may determine to reduce or eliminate the common stock dividend in the future to fund investments for growth, repurchase shares, or conserve capital resources.

Management Comments

• Our overall revenue in the second quarter of fiscal year 2025 increased by 4% compared to the second quarter of fiscal year 2024, reflecting increases in both our Diagnostics and Life Sciences segment revenue.
• The increase in our Diagnostics segment revenue for the second quarter of fiscal year 2025 was driven by our Immunodiagnostics and Reproductive Health businesses.
• The increase in our Life Sciences segment revenue for the second quarter of fiscal year 2025 was driven by increased revenue in our Software business.
• Our consolidated gross margins decreased primarily due to increased tariffs and product mix shift partially offset by pricing actions.
• Our consolidated operating margins increased primarily due to sales volume leverage and productivity gains offsetting gross margin headwinds.
• We now estimate that pursuant to the tariffs recently enacted and currently in effect, our cost of revenue for the current fiscal year could increase by approximately $25 million, but mitigating actions are expected to limit the gross margin decrease to approximately $20 million.
• We are implementing a comprehensive mitigation strategy that includes manufacturing optimization, supplier collaboration, selective pricing actions, and targeted temporary cost measures to minimize financial exposure.
• We anticipate that our internal operations will generate sufficient cash to fund our operating expenses, capital expenditures, acquisitions, interest payments on our debt and dividends on our common stock, for the foreseeable future, including at least the next 12 months.
• We expect to continue to use proceeds from the Business sale for a combination of debt retirement, opportunistic share repurchases and continued strategic and value creating acquisitions.
• In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Industry Context

Revvity operates at the forefront of health science solutions, specializing in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. The company's strategic focus on Life Sciences and Diagnostics segments aligns with broader industry trends towards precision medicine and advanced healthcare diagnostics. The reported investments in new product development and digital capabilities are consistent with the high R&D intensity and technological evolution characteristic of these sectors. The challenges faced, such as increased tariffs and foreign exchange rate fluctuations, reflect the globalized nature of the health science supply chain and market, where international trade policies and currency volatility can significantly impact operational costs and profitability.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Revvity's performance against industry standards.

Corporate Governance

Legal Proceedings

• The company is subject to various claims, legal proceedings, and investigations arising in the ordinary course of business, including product liability claims.
• Accruals for potential losses believed to be probable and reasonably estimable have been established.
• Management believes the total cost of resolving these contingencies as of June 29, 2025, should not have a material adverse effect on the condensed consolidated financial statements, though uncertainties remain.

Stakeholder Impact

• Shareholders: Positively impacted by the ongoing share repurchase program and consistent quarterly dividends, but face potential future dividend reductions and mixed financial performance with margin pressures.
• Employees: Affected by restructuring activities and investments in new product development and digital capabilities, which may lead to shifts in roles or skill requirements.
• Customers: Benefit from continued investments in new product development and digital capabilities, but may experience impacts from pricing actions taken to offset tariffs.
• Suppliers: Engaged in collaboration efforts as part of the tariff mitigation strategy, potentially leading to changes in sourcing or terms.
• Creditors: Impacted by the company's substantial debt levels and the covenants within its debt instruments, which could affect future borrowing capacity and terms.

Next Steps

• Payment of the declared quarterly cash dividend of $0.07 per share for Q2 fiscal year 2025 in August 2025.
• Payment of the declared quarterly cash dividend of $0.07 per share for Q3 fiscal year 2025 in November 2025.
• Receipt of the remaining $37.5 million Brand Fee in the second half of fiscal year 2025.
• Continued use of proceeds from the Business sale for debt retirement, opportunistic share repurchases, and strategic acquisitions.
• Implementation of a comprehensive mitigation strategy for tariffs, including manufacturing optimization, supplier collaboration, selective pricing actions, and targeted temporary cost measures.
• Ongoing evaluation of the impact of the One Big Beautiful Bill Act (OBBBA) for subsequent fiscal years.

Key Dates

Recommendation

Revvity's Q2 2025 results present a mixed picture. While the company achieved solid revenue growth across both its Life Sciences and Diagnostics segments, demonstrating demand for its specialized solutions, profitability metrics show some headwinds. Gross margins declined due to increased tariffs and product mix shifts, and net income for the quarter decreased. Operating cash flow also saw a significant reduction for the six-month period. However, the company's proactive approach to mitigating tariff impacts and its substantial share repurchase program signal management's confidence and commitment to shareholder returns. Given the strong strategic positioning in growing health science markets, balanced against current operational pressures on profitability and cash generation, a 'Hold' recommendation is appropriate. This allows investors to observe the effectiveness of the company's mitigation strategies and a clearer trend in core profitability and cash flow before making a more definitive investment decision.

Keywords

Health Science, Life Sciences, Diagnostics, Immunodiagnostics, Reproductive Health, Software, SEC Filing, Quarterly Report, Financial Results, Revenue, Earnings, Stock Repurchase, Corporate Governance, Risk Management, Biotechnology, Pharmaceutical, Healthcare, Tariffs, Cash Flow